Marker Therapeutics MRKR
NASDAQ MRKR
$1.07 -0.06 (-5.31%)
At close: Oct 22, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Preferred Stock Liabilities (2014 - 2015)

Updated

Marker Therapeutics' Preferred Stock Liabilities came in at $10 million for Q3 2015, unchanged from the prior quarter.

Analysis

Marker Therapeutics (MRKR) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Marker Therapeutics 17.87 Mn -42.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 10.00 Mn
Jun 30, 2015 10.00 Mn
Dec 31, 2014 10.00 Mn
API Access

Marker Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MRKR&period=max&api_key=YOUR_API_KEY